USANA Health Sciences (NYSE:USNA) Updates FY 2024 Earnings Guidance

USANA Health Sciences (NYSE:USNA) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 2.400-3.000 for the period, compared to the consensus earnings per share estimate of 2.720. The company issued revenue guidance of $850.0 million-$920.0 million, compared to the consensus revenue estimate of $889.8 million.

USANA Health Sciences Price Performance

Shares of USNA stock traded down $1.48 during mid-day trading on Tuesday, hitting $41.50. The company had a trading volume of 104,538 shares, compared to its average volume of 80,488. The company has a market capitalization of $798.46 million, a P/E ratio of 12.88, a P/E/G ratio of 1.33 and a beta of 0.91. The stock’s 50 day moving average price is $46.94 and its 200-day moving average price is $48.56. USANA Health Sciences has a 52-week low of $41.45 and a 52-week high of $69.60.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings results on Tuesday, February 6th. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.52 by $0.35. The company had revenue of $221.08 million during the quarter, compared to analyst estimates of $206.70 million. USANA Health Sciences had a return on equity of 13.49% and a net margin of 6.93%. On average, equities research analysts expect that USANA Health Sciences will post 2.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

USNA has been the subject of several recent research reports. DA Davidson dropped their price target on USANA Health Sciences from $53.00 to $48.00 and set a neutral rating for the company in a research report on Thursday, February 22nd. StockNews.com upgraded USANA Health Sciences from a buy rating to a strong-buy rating in a research report on Friday, January 12th.

Insider Buying and Selling at USANA Health Sciences

In other USANA Health Sciences news, insider Robert A. Sinnott sold 3,945 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $46.55, for a total transaction of $183,639.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Robert A. Sinnott sold 3,945 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $46.55, for a total value of $183,639.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider David Mulham Mulham sold 4,311 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $47.76, for a total value of $205,893.36. Following the completion of the sale, the insider now owns 7,825 shares of the company’s stock, valued at approximately $373,722. The disclosure for this sale can be found here. Insiders sold 24,807 shares of company stock worth $1,200,791 over the last 90 days. Company insiders own 0.33% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.